公开(公告)号：WO2007070546A3

公开(公告)日：2007-08-16

申请号：PCT/US2006047473

申请日：2006-12-13

Applicant: ANIKA THERAPEUTICS INC ,  SADOZAI KHALID K ,  TOTH CAROL A

Inventor： SADOZAI KHALID K ,  TOTH CAROL A

IPC: A61F2/38 ,  A61K31/728 ,  A61L27/20 ,  A61P19/02

CPC classification number: A61L27/3843 ,  A61K9/0024 ,  A61K9/06 ,  A61K31/573 ,  A61K31/728 ,  A61K31/729 ,  A61K35/28 ,  A61K35/32 ,  A61K38/1841 ,  A61K47/36 ,  A61L27/20 ,  A61L27/227 ,  A61L27/3817 ,  A61L27/3834 ,  A61L27/48 ,  A61L27/52 ,  A61L27/56 ,  A61L2430/06 ,  C08L5/08 ,  A61K2300/00

Abstract: A composite for treating an articular defect includes a hyaluronic acid derivative; and at least one member of the group consisting of a cell, a cellular growth factor and a cellular differentiation factor, which is impregnated in, or coupled to. the hyaluronic acid derivative. In one embodiment, carboxyl functionalities of the hyaluronic acid derivative are each independently derivatized to include an N-acylurea or O-acyl isourea, or both N-acylurea and O-acyl isourea. In another embodiment, the hyaluronic acid derivative is prepared by reacting an uncrosslinked hyaluronic acid with a biscarbodimide in the presence of a pH buffer in a range of between about 4 and about 8. The composite can be used for regenerating or stimulating regeneration of meniscal tissues in a subject in need thereof.

Abstract translation: 用于治疗关节缺损的复合物包括透明质酸衍生物; 以及由细胞，细胞生长因子和细胞分化因子组成的组中的至少一个成员，其被浸渍或偶联。 透明质酸衍生物。 在一个实施方案中，透明质酸衍生物的羧基官能度各自独立地衍生化为包括N-酰基脲或O-酰基异脲，或N-酰基脲和O-酰基异脲二者。 在另一个实施方案中，透明质酸衍生物通过在约4至约8范围内的pH缓冲剂存在下使未交联的透明质酸与双碳酰亚胺反应来制备。该复合物可用于再生或刺激半月板组织的再生 在有需要的受试者中。

公开(公告)号：WO2006029406A3

公开(公告)日：2006-06-22

申请号：PCT/US2005032521

申请日：2005-09-09

Applicant: STRYKER CORP ,  LEE JOHN C ,  TOTH CAROL A

Inventor： LEE JOHN C ,  TOTH CAROL A

IPC: A61K38/18

CPC classification number: A61K38/1875 ,  A61K48/00

Abstract: The present invention provides methods of treating bone cancer, inducing differentiation of bone tumor cells, inhibiting bone tumor growth, inducing bone tumor regression or treating a hyperproliferative cell disorder by administering a pharmaceutically effective amount of a bone morphogenic protein or a nucleic acid encoding the bone morphogenic protein.

Abstract translation: 本发明提供了通过施用药学有效量的骨形态发生蛋白或编码骨的核酸来治疗骨癌，诱导骨肿瘤细胞分化，抑制骨肿瘤生长，诱导骨肿瘤消退或治疗过度增殖性细胞病症的方法 形态发生蛋白。